DLX5 and lymphoma: It was shown that more than 50% of compounds which wereselected by docking technique are capable at micro-molar concentrations to inhibitthe proliferation of mouse lymphoma cells expressing Dlx5 .Moreover, most of the compounds active on Dlx5 positive lymphoma cells had no effecton other types of cells that do not express this transcription factor, which servesas evidence of the specificity of the selected molecules.